Fatty Liver Study in Patients With Type II Diabetes

Status Terminated

Clinical Trial Summary

The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.

Clinical Trial Description

In patients with type 2 diabetes whose glycemic control is not accomplished with Metformin alone, there are several options for additional hypoglycemic agent. As per recent National guidelines at least three "second line" agents can be added to metformin: thiazolidinediones, Lantus insulin, and DPP4 inhibitors. All three approaches have been proven to help accomplishing goals of therapy for glycemic control (HbA1c<7%) in clinical trials. Whether one approach is superior to the other in improving associated non-glycemic metabolic abnormalities and risk for future morbidity and mortality in patients with type 2 diabetes remains a matter of intense debate. Among these abnormalities, excessive triglyceride content in the liver (fatty liver or liver steatosis) is a major predictor of risk for non-alcoholic steato-hepatitis (NASH) and liver cirrhosis. Fatty liver is highly prevalent in patients with type 2 diabetes. There are no clinical studies done to determine if any of these three therapeutic options is superior at reducing the liver triglyceride content in patients with type 2 diabetes and fatty Liver. Therefore, in this study we propose to measure and compare the effects on liver triglyceride content when either pioglitazone, lantus insulin, or DPP4 inhibitors are added to metformin in patients with poorly controlled type 2 diabetes (HbA1c>7.6%) and fatty liver (presence of "bright" liver in abdominal ultrasound). The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02365233
Study type	Interventional
Source	The University of Texas Medical Branch, Galveston
Contact
Status	Terminated
Phase	Phase 4
Start date	May 1, 2013
Completion date	December 31, 2016

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04569214` - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients	Phase 2
Completed	`NCT02127762` - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy	N/A
Completed	`NCT01698528` - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration	N/A
Completed	`NCT00985114` - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity	N/A
Active, not recruiting	`NCT05120219` - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers	Phase 1
Completed	`NCT04893135` - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes	N/A
Not yet recruiting	`NCT05108350` - A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects	Phase 1
Completed	`NCT02586129` - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes	Phase 3
Completed	`NCT02914743` - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes	N/A
Completed	`NCT04540016` - Mass Balance and Biotransformation of [14C]HSK7653 in Human	Phase 1
Completed	`NCT02429258` - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin	Phase 4
Completed	`NCT01055223` - Fracture Risk With Thiazolidinediones	N/A
Completed	`NCT05878587` - Burger Allen Exercises in Knee OA With Type II Diabetes	N/A
Completed	`NCT04768673` - A Study to Investigate the PK and Safety of CKD-393	Phase 1
Not yet recruiting	`NCT05028140` - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus	Phase 3
Terminated	`NCT01804777` - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes	Early Phase 1
Completed	`NCT01619332` - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763	Phase 1/Phase 2
Active, not recruiting	`NCT06387433` - Effectiveness of an mHealth Mobile App	N/A
Completed	`NCT01881074` - Periodontal Treatment Response in Type II Diabetic Patients
Not yet recruiting	`NCT01591525` - Diabetes Mellitus Community Based Screening in Minority Populations	N/A